Santhera Explores Strategic Options; Updates Financial Calendar

2013-02-28 07:16:27 -
Santhera Pharmaceuticals Holding AG /
Santhera Explores Strategic Options; Updates Financial Calendar
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 


Liestal, Switzerland, February 28, 2013 - Santhera Pharmaceuticals (SIX: SANN)
announced today that following the voluntary withdrawal of Catena(®) from the
Canadian market and the earlier negative decision of the Committee for Medicinal
Products for Human Use (CHMP) on the Market Authorization Application for
Raxone(®) in Leber's Hereditary Optic Neuropathy (LHON), the Board has decided
to consider strategic options including product licensing for Raxone(®) in LHON
and the possibility of a merger or acquisition. Santhera has already received
expressions of interest from third parties and has retained Piper Jaffray
Limited to assist the Company in this process.

The publication of the financial results 
  
    
      
        

	    
  
  for 2012 will be postponed and,
together with the financial outlook for 2013, will now be provided within the
timelines required by the SIX regulations. Accordingly, the Company will
therefore postpone the Annual Shareholders' Meeting previously planned for
April 22, 2013.

Shareholders should note that whilst the Board believes that it is in the best
interest of shareholders to explore these options and take the steps described,
there can be no guarantee that any transaction can be consummated.

                                     * * *
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company
focused on the development and commercialization of innovative pharmaceutical
products for the treatment of orphan neuromuscular and mitochondrial diseases,
areas of high unmet medical need with no current therapies. For further
information, please visit www.santhera.com.

For further information, contact
Thomas Meier, Chief Executive Officer
Phone: +41 61 906 89 64
thomas.meier@santhera.com

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore not place
undue reliance on these statements, particularly not in connection with any
contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.


News release: 
 hugin.info/137261/R/1681770/549895.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Santhera Pharmaceuticals Holding AG via Thomson Reuters ONE
[HUG#1681770]